Lorvotuzumab

Modify Date: 2024-01-13 15:45:24

Lorvotuzumab structure	Common Name	Lorvotuzumab
	CAS Number	339306-30-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Lorvotuzumab

Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].

Name	Lorvotuzumab

Description	Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Lorvotuzumab mertansine (IMGN901) 是一种 ADC，可通过二硫键连接强效抗有丝分裂 (DM1) 与 CD56 靶向抗体 (Lorvotuzumab)。 Lorvotuzumab mertansine 抗肾母细胞瘤、横纹肌肉瘤和神经母细胞瘤。
References	[1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310.

No Any Chemical & Physical Properties

Lorvotuzumab

Use of Lorvotuzumab

Names

Lorvotuzumab Biological Activity

Chemical & Physical Properties